Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Inclusion Criteria:

Adult males with metastatic prostate cancer
ECOG performance score 0-2
Stable androgen deprivation or other hormone therapy (30 days) or therapy planned but not yet initiated

PSMA PET scan between 3 and 28 days prior to radiotracer injection with at least 2 PSMA positive lesions and either:

One soft tissue lesion measuring ≥ 15 mm in the longest diameter with SUVmax lesion ≥ SUVmean normal liver, OR
Two bone lesions measuring ≥ 15 mm in the longest diameter with SUVmax lesion ≥ 2 x SUVmax normal liver
Able to understand and adhere to study requirements, and voluntarily give informed consent

Exclusion Criteria:

No other malignancy undergoing treatment
No PSMA-targeted therapy ongoing
Inability or unwillingness to undergo SPECT/CT imaging
Serum creatinine > 1.5 mg/dL or creatinine clearance ≤50 mL/min by Cockcroft-Gault estimation
Concurrent participation in the active treatment phase of another clinical trial of investigational medicinal product(s)
Significant intercurrent illness, treatment-related toxicity, or psychiatric illness/social situation that could place the subject at undue risk during study participation, significantly alter study outcomes, or affect subject compliance with study requirements for dosing and evaluation, as determined by the investigator